HER2 negative locally advanced unresectable or metastatic G/GEJ adenocarcinoma. 69.5% male, 35% with age ≥ 65 years, 32.4% ECOG 0, 75% from Asia, and 25% from Europe and North America. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.